Quest Diagnostics (MIL:1QDX) NonCurrent Deferred Liabilities: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1QDX Quest Diagnostics Inc MIL:1QDX
54 GF Score
Price €180.35
GF Value €163.64
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Quest Diagnostics NonCurrent Deferred Liabilities?

Quest Diagnostics MIL:1QDX 54 NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus rates MIL:1QDX with a GF Score™ of 54/100 and a GF Value™ of €163.64 (Fairly Valued). The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Quest Diagnostics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €0 Mil.

Quest Diagnostics NonCurrent Deferred Liabilities Related Terms

Quest Diagnostics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Quest Diagnostics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Diagnostics NonCurrent Deferred Liabilities Chart

Quest Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Quest Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:1QDX
54GF Score
Quest Diagnostics Inc MIL:1QDX
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0 Mil mean?
Quest Diagnostics (MIL:1QDX) has a NonCurrent Deferred Liabilities of €0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Quest Diagnostics and its competitors.
Is Quest Diagnostics' NonCurrent Deferred Liabilities too high?
Quest Diagnostics' current NonCurrent Deferred Liabilities is €0 Mil. Overall, Quest Diagnostics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' NonCurrent Deferred Liabilities compare to LH and MTD?
Quest Diagnostics' NonCurrent Deferred Liabilities of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current NonCurrent Deferred Liabilities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (MIL:1QDX) is currently considered Fairly Valued. The stock's GF Value™ is €163.64, compared to a current price of €180.35 — trading 10.2% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0 Mil. Quest Diagnostics' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Quest Diagnostics (MIL:1QDX), the current NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Quest Diagnostics (MIL:1QDX) Overvalued in 2026?

Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued. The current stock price of €180.35 is trading 10.2% above its estimated GF Value™ of €163.64. GuruFocus considers Quest Diagnostics to be Fairly Valued.

Key valuation signals for MIL:1QDX:

  • NonCurrent Deferred Liabilities: €0 Mil
  • GF Value™: €163.64 vs. price of €180.35 (10.2% above fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the MIL:1QDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Quest Diagnostics Business Description

Address 500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
54GF Score

Get the complete analysis for MIL:1QDX

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€180.35
Price
€163.64
GF Value